Compare Abeona Therapeutics Inc (ABEO) vs Angi Inc (ANGI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Angi Inc — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while Angi Inc trades at $6.03 (market cap $260.08M). The key difference: Abeona Therapeutics Inc is the larger of the two by market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Angi Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | ANGI | |
|---|---|---|
Market Cap | $373.32M | $260.08M |
Sector | Health | Media |
52-Week High | $7.23 | $18.90 |
52-Week Low | $4.17 | $4.78 |
Enterprise Value | $228.22M | $486.89M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
ANGI trades at $6.44, up 6.27% today, with a bullish technical signal from moving averages but mixed oscillators. Revenue declined to $1.03B in 2025, though net income improved to $43.83M. Valuation ratios appear low with P/E of 14.86 and P/S of 0.27. Recent news highlights an AI strategy pivot and multiple law firm fraud investigations, creating uncertainty.
The stock offers potential upside to the $9.20 consensus price target, but risks include declining revenue, negative cash flows, and legal scrutiny. Analyst sentiment is cautious with 62.97% hold ratings. Execution of the AI transition and resolution of legal issues are critical for future performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Angi Inc
Angi Inc connects quality home service professionals across different categories, from repairing and remodeling to cleaning and landscaping, with consumers. It has two geographical segments namely North America (the United States and Canada), which primarily includes the operations HomeAdvisor, Angie's List, Handy, mHelpDesk, HomeStars, and Fixd Repair
Read more on ANGI →
